Scilex Holding (SCLX) Cash & Current Investments (2020 - 2026)
Scilex Holding (SCLX) posted quarterly Cash & Current Investments of $145.1 million for Q1 2026, up 2401.26% year-over-year from $5.8 million in Q1 2025, and up 1200.52% on a QoQ basis from $11.2 million in Q4 2025.
Scilex Holding (SCLX) Cash & Current Investments (2020 - 2026) Analysis & Trends
Scilex Holding (SCLX) has reported Cash & Current Investments for 7 consecutive years, with $145.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash & Current Investments rose 2401.26% year-over-year to $145.1 million; the TTM figure through Mar 2026 stood at $145.1 million (up 2401.26% YoY), while the FY2025 annual figure was $11.2 million, up 240.92% from the prior year.
- Cash & Current Investments came in at $145.1 million for Q1 2026 at Scilex Holding, up from $11.2 million in the prior quarter.
- The five-year high for Cash & Current Investments was $145.1 million in Q1 2026, with the low at $69922.0 in Q3 2022.
- Average Cash & Current Investments over 5 years is $29.9 million, with a median of $4.1 million recorded in 2025.
- The largest YoY upside for Cash & Current Investments was 55034.43% in 2022 against a maximum downside of 98.48% in 2022.
- Year by year, Cash & Current Investments stood at $2.2 million in 2022, then surged by 79.53% to $3.9 million in 2023, then retreated by 16.55% to $3.3 million in 2024, then surged by 240.92% to $11.2 million in 2025, then surged by 1200.52% to $145.1 million in 2026.
- According to Business Quant data, Cash & Current Investments over the past three periods registered $145.1 million, $11.2 million, and $900000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 5.28 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 22.05 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 9.39 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 7.94 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 5.70 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 12.04 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 7.64 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 13.08 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | 100.00 Mn |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn | 145.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 145.07 Mn |
| Dec 31, 2025 | 11.16 Mn |
| Sep 30, 2025 | 900,000.00 |
| Jun 30, 2025 | 4.10 Mn |
| Mar 31, 2025 | 5.80 Mn |
| Dec 31, 2024 | 3.27 Mn |
| Sep 30, 2024 | 77,000.00 |
| Jun 30, 2024 | 6.89 Mn |
| Mar 31, 2024 | 1.82 Mn |
| Dec 31, 2023 | 3.92 Mn |
| Sep 30, 2023 | 2.00 Mn |
| Jun 30, 2023 | 34.12 Mn |
| Mar 31, 2023 | 5.10 Mn |
| Dec 31, 2022 | 2.18 Mn |
| Sep 30, 2022 | 69,922.00 |
| Jun 30, 2022 | 142.04 Mn |
| Mar 31, 2022 | 140.58 Mn |
| Dec 31, 2021 | 143.75 Mn |
| Sep 30, 2021 | 115,642.00 |
| Jun 30, 2021 | 257,621.00 |